公开(公告)号：US20140080869A1

公开(公告)日：2014-03-20

申请号：US14029324

申请日：2013-09-17

Applicant: AbbVie Inc.

Inventor： Preethi KRISHNAN ,  Teresa (Iok-Chan) NG ,  Tami J. PILOT-MATIAS ,  Warren M. KATI ,  Clarence J. MARING ,  Neeta C. MISTRY ,  Thomas J. REISCH ,  Rolf WAGNER ,  Dachun LIU ,  John K. PRATT ,  Mark A. Matulenko ,  Ryan G. KEDDY

IPC: A61K31/454 ,  A61K45/06

CPC classification number: A61K31/454 ,  A61K31/4184 ,  A61K45/06 ,  A61K2300/00

Abstract: Pan-genotypic HCV inhibitors are described. This invention also relates to methods of using these inhibitors to treat HCV infection.

公开(公告)号：US20140080868A1

公开(公告)日：2014-03-20

申请号：US14029302

申请日：2013-09-17

Applicant: AbbVie Inc.

Inventor： Theresea (Iok-Chan) NG ,  Tami J. PILOT-MATIAS ,  Warren M. KATI ,  Preethi KRISHNAN ,  Clarence J. MARING ,  Neeta C. MISTRY ,  Thomas J. REISCH ,  Rolf WAGNER ,  Dachun LIU ,  John K. PRATT ,  Mark A. MATULENKO ,  Ryan G. KEDDY

IPC: A61K31/454 ,  A61K45/06

CPC classification number: A61K31/454 ,  A61K31/4184 ,  A61K45/06 ,  A61P31/14 ,  A61K2300/00

Abstract: Pan-genotypic HCV inhibitors are described. This invention also relates to methods of using these inhibitors to treat HCV infection.

Abstract translation: 描述了泛基因型HCV抑制剂。 本发明还涉及使用这些抑制剂治疗HCV感染的方法。

公开(公告)号：US20140213601A1

公开(公告)日：2014-07-31

申请号：US14021435

申请日：2013-09-09

Applicant: ABBVIE INC.

Inventor： David A. DEGOEY ,  Pamela L. DONNER ,  Warren M. KATI ,  Charles W. HUTCHINS ,  Mark A. MATULENKO ,  Tammie K. JINKERSON ,  Ryan G. KEDDY

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

公开(公告)号：US20140213595A1

公开(公告)日：2014-07-31

申请号：US14017901

申请日：2013-09-04

Applicant: ABBVIE INC.

Inventor： David A. DEGOEY ,  Pamela L. DONNER ,  Warren M. KATI ,  Charles W. HUTCHINS ,  Allan C. KRUEGER ,  John T. RANDOLPH ,  Christopher E. MOTTER ,  Preethi KRISHNAN ,  Neeta C. MISTRY ,  Tami J. PILOT-MATIAS ,  Sachin V. PATEL ,  Xiaoyan LI ,  Todd N. SOLTWEDEL ,  Lissa T. NELSON

IPC: C07D471/04 ,  C07D239/48

CPC classification number: C07D471/04 ,  C07D239/48

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Abstract translation: 描述了有效抑制丙型肝炎病毒（“HCV”）复制的化合物。 本发明还涉及制备这种化合物的方法，包含这些化合物的组合物，以及使用这些化合物治疗HCV感染的方法。

公开(公告)号：US20140162971A1

公开(公告)日：2014-06-12

申请号：US13828285

申请日：2013-03-14

Applicant: ABBVIE INC.

Inventor： Le WANG ,  John K PRATT ,  Keith F. McDANIEL ,  Yujia DAI ,  Steven D FIDANZE ,  Lisa HASVOLD ,  John H. Holms ,  Warren M. KATI ,  Dachun LIU ,  Robert A Mantei ,  William J. McCLELLAN ,  George S. SHEPPARD ,  Carol K. Wada

IPC: C07D471/04 ,  A61K31/5377 ,  A61K45/06 ,  C07D487/04 ,  A61K31/5025 ,  A61K31/437 ,  A61K31/541

CPC classification number: A61K31/541 ,  A61K31/437 ,  A61K31/5025 ,  A61K31/5377 ,  A61K45/06 ,  C07D471/04 ,  C07D487/04

Abstract: The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

Abstract translation: 本发明提供式（I）化合物，其中A1，A2，A3，A4，X1，X2，Y1，L1，G1，Rx和Ry具有说明书中定义的任何值及其药学上可接受的盐 ，其作为治疗疾病和病症（包括炎性疾病，癌症和AIDS）的药剂是有用的。 还提供了包含一种或多种式（I）化合物的药物组合物。

公开(公告)号：US20140155382A1

公开(公告)日：2014-06-05

申请号：US14087480

申请日：2013-11-22

Applicant: ABBVIE INC.

Inventor： David A. DEGOEY ,  Allan C. KRUEGER ,  Charles W. HUTCHINS ,  Warren M. KATI ,  William A. CARROLL

IPC: A61K31/55 ,  A61K31/422 ,  A61K31/4184 ,  A61K31/4178 ,  A61K45/06 ,  C07D487/04 ,  C07D417/14 ,  C07D413/12 ,  C07D403/14 ,  C07D207/16 ,  A61K31/506 ,  A61K31/4025

CPC classification number: A61K31/55 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/506 ,  A61K38/00 ,  A61K45/06 ,  C07D205/04 ,  C07D207/16 ,  C07D207/22 ,  C07D209/52 ,  C07D211/60 ,  C07D263/06 ,  C07D277/06 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04 ,  C07K5/06034 ,  C07K5/06043 ,  C07K5/0606 ,  C07K5/06069 ,  C07K5/06078 ,  C07K5/06139

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.